Malkin D, Jolly K W, Barbier N, Look A T, Friend S H, Gebhardt M C, Andersen T I, Børresen A L, Li F P, Garber J
Division of Molecular Genetics, Massachusetts General Hospital Cancer Center, Boston.
N Engl J Med. 1992 May 14;326(20):1309-15. doi: 10.1056/NEJM199205143262002.
Acquired mutations in the p53 tumor-suppressor gene have been detected in several human cancers, including colon, breast, and lung cancer. Inherited mutations (transmitted through the germline) of this gene can underlie the Li-Fraumeni syndrome, a rare familial association of breast cancer in young women, childhood sarcomas, and other malignant neoplasms. We investigated the possibility that p53 mutations in the germline are associated with second primary cancers that arise in children and young adults who would not be considered as belonging to Li-Fraumeni families.
Genomic DNA was extracted from the blood leukocytes of 59 children and young adults with a second primary cancer. The polymerase chain reaction, in combination with denaturant-gel electrophoresis and sequencing, was used to identify p53 gene mutations.
Mutations of p53 that changed the predicted amino acid sequence were identified in leukocyte DNA from 4 of the 59 patients (6.8 percent). In three cases, the mutations were identical to ones previously found in the p53 gene. The fourth mutation was the first germline mutation to be identified in exon 9, at codon 325. Analysis of leukocyte DNA from close relatives of three of the patients indicated that the mutations were inherited, but cancer had developed in only one parent at the start of the study.
These findings identify an important subgroup of young patients with cancer who carry germline mutations in the p53 tumor-suppressor gene but whose family histories are not indicative of the Li-Fraumeni syndrome. The early detection of such mutations would be useful not only in treating these patients, but also in identifying family members who may be at high risk for the development of tumors.
在包括结肠癌、乳腺癌和肺癌在内的多种人类癌症中已检测到p53肿瘤抑制基因的获得性突变。该基因的遗传性突变(通过种系传递)可能是李-弗劳梅尼综合征的基础,这是一种年轻女性乳腺癌、儿童肉瘤和其他恶性肿瘤的罕见家族性关联疾病。我们研究了种系中p53突变与儿童和年轻成人发生的第二原发性癌症相关的可能性,这些儿童和年轻成人不被认为属于李-弗劳梅尼家族。
从59名患有第二原发性癌症的儿童和年轻成人的血液白细胞中提取基因组DNA。采用聚合酶链反应结合变性凝胶电泳和测序来鉴定p53基因突变。
在59例患者中的4例(6.8%)白细胞DNA中鉴定出改变预测氨基酸序列的p53突变。在3例中,这些突变与先前在p53基因中发现的突变相同。第四个突变是在第9外显子第325密码子处鉴定出的首个种系突变。对其中3例患者近亲的白细胞DNA分析表明这些突变是遗传的,但在研究开始时只有一位父母患癌。
这些发现确定了一个重要的年轻癌症患者亚组,他们携带p53肿瘤抑制基因的种系突变,但其家族史并不表明患有李-弗劳梅尼综合征。早期检测此类突变不仅对治疗这些患者有用,而且对识别可能有高肿瘤发生风险的家庭成员也有用。